TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19240664

Group type: EXPERIMENTAL
Intervention: Porous coated motion (PCM) artificial cervical disc in primary patients (no previous fusion)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Porous coated motion (PCM) artificial cervical disc in adjacent level fusion patients
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Revision surgery
Number of subjects: 152
Study: 17480179

Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 0
Study: 14742982

Group type: EXPERIMENTAL
Intervention: Iron supplements with morning dose of MMF (n=14)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Iron supplements given 4 hr after MMF at midday (n=13)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No iron supplements (n=13)
Number of subjects: 40
Study: 11577951

Group type: EXPERIMENTAL
Intervention: Hyaluronan in surgical group
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group in surgical treatment
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Hyaluronan in non-surgical group
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group in non-surgical treatment
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Surgical and non-surgical groups
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Hyaluronan
Number of subjects: 15
Study: 9628449

Group type: EXPERIMENTAL
Intervention: Enoxaparin (30 mg IV bolus followed by SC injections of 1.0 mg/kg every 12 hours)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unfractionated heparin (70 U/kg bolus followed by infusion of 15 U/kg per hour)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enoxaparin (fixed-dose SC enoxaparin 60 mg every 12 hours for patients ≤65 kg, 40 mg every 12 hours for patients <65 kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 0
Study: 8051381

Group type: EXPERIMENTAL
Intervention: malotilate 1500 mg/day
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: malotilate 750 mg/day
Number of subjects: 407

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 407
Study: 2723511

Group type: EXPERIMENTAL
Intervention: Single-lumen needle (SLN)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Double-lumen needle (DLN)
Number of subjects: 44
Study: 20034170

Group type: EXPERIMENTAL
Intervention: Oxazepam (60-120 mg daily)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 31997704

Group type: EXPERIMENTAL
Intervention: Nasal administration of vasopressin (AVP)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Child's birth
Number of subjects: 25
Study: 31958773

Group type: EXPERIMENTAL
Intervention: Higher plasma S-Klotho concentrations in middle-aged adults
Number of subjects: 214

Group type: COMPARATOR
Intervention: Higher plasma S-Klotho concentrations in young adults
Number of subjects: 214
Study: 31818843

Group type: EXPERIMENTAL
Intervention: Simultaneous resection of the primary pancreatic cancer lesion and liver oligometastases
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard chemotherapy
Number of subjects: 300
Study: 27696786

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Secukinumab 75 mg
Number of subjects: 606

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 606
Study: 25437533

Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg once daily
Number of subjects: 742

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 742
Study: 24006882

Group type: EXPERIMENTAL
Intervention: Cervical cancer with cause specified (HPV, a STI)
Number of subjects: 478

Group type: COMPARATOR
Intervention: Cervical cancer with cause unspecified
Number of subjects: 478
Study: 21288628

Group type: EXPERIMENTAL
Intervention: EE 20 μg/drsp 3mg COC (n=451)
Number of subjects: 893

Group type: COMPARATOR
Intervention: Placebo (n=442)
Number of subjects: 893
Study: 19473905

Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation programme (Gp A)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Standard physical therapy (Gp B)
Number of subjects: 107
Study: 17093248

Group type: EXPERIMENTAL
Intervention: Rabbit antithymocyte globulin (1.5 mg/kg daily for 5 days)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Basiliximab (20 mg on days 0 and 4)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Rabbit antithymocyte globulin
Number of subjects: 278

Group type: COMPARATOR
Intervention: Basiliximab
Number of subjects: 278
Study: 15462699

Group type: EXPERIMENTAL
Intervention: Montelukast 5 mg once daily
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 11172151

Group type: EXPERIMENTAL
Intervention: Intracoronary radiation therapy with iridium-192
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo (nonradioactive ribbon)
Number of subjects: 252
Study: 9506734

Group type: EXPERIMENTAL
Intervention: Troglitazone (200‐800 mg daily)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 7710471

Group type: EXPERIMENTAL
Intervention: Marlex mesh
Number of subjects: 102

Group type: COMPARATOR
Intervention: Primary closure
Number of subjects: 102
Study: 2454038

Group type: EXPERIMENTAL
Intervention: Cladosporium immunotherapy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 1073187

Group type: EXPERIMENTAL
Intervention: alexidine dihydrochloride oral rinse
Number of subjects: 167

Group type: COMPARATOR
Intervention: placebo oral rinse
Number of subjects: 167
Study: 30466306

Group type: EXPERIMENTAL
Intervention: Modified semiblind fasciotomy of the anterior compartment
Number of subjects: 64
Study: 29343693

Group type: EXPERIMENTAL
Intervention: Real acupuncture (REAL)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Phantom acupuncture (PHNT)
Number of subjects: 56
Study: 27638148

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups (including LLLT, control, and placebo)
Number of subjects: 60
Study: 24486163

Group type: EXPERIMENTAL
Intervention: Hospital-at-home treatment
Number of subjects: 139

Group type: COMPARATOR
Intervention: Usual hospital care
Number of subjects: 139
Study: 22998716

Group type: EXPERIMENTAL
Intervention: Clinically indicated replacement
Number of subjects: 3283

Group type: COMPARATOR
Intervention: Routine replacement
Number of subjects: 3283
Study: 19936767

Group type: EXPERIMENTAL
Intervention: Chronomodulated chemotherapy
Number of subjects: 958

Group type: COMPARATOR
Intervention: Conventional chemotherapy
Number of subjects: 958
Study: 17336373

Group type: EXPERIMENTAL
Intervention: Educational video intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: No educational video intervention (Control)
Number of subjects: 100
Study: 16336029

Group type: EXPERIMENTAL
Intervention: Tulobuterol (2mg once-daily applied as a patch)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Salmeterol (50 microg per inhalation, twice a day)
Number of subjects: 92
Study: 11882468

Group type: EXPERIMENTAL
Intervention: Milk consumption (mean 50 g/day, 95% CI 44-55 g/day)
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: Milk consumption (varied by region: rural 9 g/day, suburban 36 g/day, urban 83 g/day)
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: Milk consumption as a dietary factor
Number of subjects: 649
Study: 10612357

Group type: EXPERIMENTAL
Intervention: Tiagabine (TGB; Gabitril) at doses of 32 mg/day and 56 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tiagabine (TGB; Gabitril) administered twice, three times, and four times daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tiagabine (TGB; Gabitril)
Number of subjects: 0
Study: 8574231

Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 2278377

Group type: EXPERIMENTAL
Intervention: Continuous morphine application (0.5-1.0 microgram/kg per min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Bolus morphine injections (0.05 mg/kg)
Number of subjects: 12
Study: 6118666

Group type: EXPERIMENTAL
Intervention: Intra-articular yttrium-90 (5 mCi) plus steroid (triamcinolone hexacetonide, 20 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline plus steroid (control)
Number of subjects: 15
Study: 31478436

Group type: EXPERIMENTAL
Intervention: 10-month high-intensity interval neuromuscular training programme (DoIT)
Number of subjects: 49
Study: 30291016

Group type: EXPERIMENTAL
Intervention: Multimodality weight gain prevention intervention (10 weekly peer-support sessions)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 39
Study: 28272228

Group type: EXPERIMENTAL
Intervention: Propofol/remifentanil (PR)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sevoflurane/remifentanil (SR)
Number of subjects: 50
Study: 25041234

Group type: EXPERIMENTAL
Intervention: Ranolazine (500 mg twice a day for 8 weeks)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 24713310

Group type: EXPERIMENTAL
Intervention: Tapentadol sustained-release (SR) [average daily dose 433 (31) mg]
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 22797188

Group type: EXPERIMENTAL
Intervention: 35 mg of risedronate weekly
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 20680681

Group type: EXPERIMENTAL
Intervention: Epirubicin plus tamoxifen
Number of subjects: 191

Group type: COMPARATOR
Intervention: Epirubicin alone
Number of subjects: 191
Study: 17414245

Group type: EXPERIMENTAL
Intervention: Bupropion SR
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bupropion SR (post hoc analysis)
Number of subjects: 30
Study: 15969759

Group type: EXPERIMENTAL
Intervention: Calcium-fortified beverage (1,125 mg Ca++/d)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (free-living)
Number of subjects: 37
Study: 12171747

Group type: EXPERIMENTAL
Intervention: Evidence from randomised controlled trials (RCTs) and systematic reviews of RCTs
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Non-randomised quantitative studies and qualitative studies
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Economic evaluations
Number of subjects: 124
Study: 9718289

Group type: EXPERIMENTAL
Intervention: D-cycloserine (500 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 7663789

Group type: EXPERIMENTAL
Intervention: Four measurements taken 8 hours apart
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Two measurements (one upon arising and one 12 hours later or before retiring)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Full 24-hour lung function profile (thirteen 2-hourly measurements)
Number of subjects: 20
Study: 2758900

Group type: EXPERIMENTAL
Intervention: Intrapartum saline amnio-infusion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no amnio-infusion)
Number of subjects: 60
Study: 435349

Group type: EXPERIMENTAL
Intervention: Suxamethonium infusion at 0.25 mg s‐1 to 20 mg s‐1
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 30-mg i.v. bolus dose of Suxamethonium
Number of subjects: 42
Study: 30896030

Group type: EXPERIMENTAL
Intervention: Mindfulness based stress reduction (mbsr)
Number of subjects: 148
Study: 28752575

Group type: EXPERIMENTAL
Intervention: IPL (BBL™ BroadBand Light; Sciton, Palo Alto, CA)
Number of subjects: 15

Group type: COMPARATOR
Intervention: PDL (Cynergy™; Cynosure, Westford, MA)
Number of subjects: 15
Study: 25618476

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Cognitive Therapy
Number of subjects: 48
Study: 24245598

Group type: EXPERIMENTAL
Intervention: The Girlfriends Project (TGP) intervention
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 149
Study: 21714697

Group type: EXPERIMENTAL
Intervention: Extended letrozole regimen (5 mg/day during the first 5 days of cycle and 2.5 mg/day during the subsequent 3 days) combined with HPuFSH-GnRHant protocol
Number of subjects: 136

Group type: COMPARATOR
Intervention: Short letrozole regimen (2.5 mg/day from cycle day 3-7) combined with HPuFSH-GnRHant protocol
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Extended letrozole regimen
Number of subjects: 136

Group type: COMPARATOR
Intervention: Short letrozole regimen
Number of subjects: 136
Study: 19187616

Group type: EXPERIMENTAL
Intervention: Remifentanil 2 microg/kg
Number of subjects: 102

Group type: COMPARATOR
Intervention: Fentanyl 2 microg/kg
Number of subjects: 102
Study: 19011013

Group type: EXPERIMENTAL
Intervention: Temporal incision
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Nasal incision
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Superior incision
Number of subjects: 110

Group type: COMPARATOR
Intervention: All incision types
Number of subjects: 110
Study: 16306073

Group type: EXPERIMENTAL
Intervention: Integrated Management of Childhood Illness (IMCI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison districts (without IMCI)
Number of subjects: 0
Study: 12201832

Group type: EXPERIMENTAL
Intervention: 10, 15 or 20 mg of pegvisomant
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 9667343

Group type: EXPERIMENTAL
Intervention: CSE-Q kit with modified technique
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CSE-S kit with modified technique
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CSE-Q kit with upward orientation of epidural needle bevel
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CSE-S kit with upward orientation of epidural needle bevel
Number of subjects: 20
Study: 7642860

Group type: EXPERIMENTAL
Intervention: Primary angioplasty
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Follow-up costs after primary angioplasty
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Repeat coronary angiography
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Repeat angioplasty
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Bypass surgery
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Correlates of higher baseline hospital costs
Number of subjects: 270
Study: 2760255

Group type: EXPERIMENTAL
Intervention: Weightlessness during parabolic flight
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weightlessness in semi-supine posture
Number of subjects: 0
Study: 145212

Group type: EXPERIMENTAL
Intervention: Deanol acetamidobenzoate
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Physostigmine salicylate
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Benztropine mesylate
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 11793023

Group type: EXPERIMENTAL
Intervention: rosiglitazone, 8 mg/day (n = 15)
Number of subjects: 29
Study: 30767166

Group type: EXPERIMENTAL
Intervention: IV paracetamol
Number of subjects: 190

Group type: COMPARATOR
Intervention: IV fentanyl
Number of subjects: 190
Study: 28984634

Group type: EXPERIMENTAL
Intervention: eHealth knowledge base in addition to standard care
Number of subjects: 208

Group type: COMPARATOR
Intervention: Standard antenatal care
Number of subjects: 208
Study: 27636505

Group type: EXPERIMENTAL
Intervention: Screening arm (SA)
Number of subjects: 442

Group type: COMPARATOR
Intervention: Control arm (CA)
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 442
Study: 24316262

Group type: EXPERIMENTAL
Intervention: Telaprevir 1125 mg twice daily
Number of subjects: 740

Group type: COMPARATOR
Intervention: Telaprevir 750 mg every 8 hours
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Telaprevir (both regimens)
Number of subjects: 740
Study: 22699675

Group type: EXPERIMENTAL
Intervention: Xylitol wipes
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo wipes
Number of subjects: 44
Study: 20194386

Group type: EXPERIMENTAL
Intervention: 35 percent hydrogen peroxide immediately after bleaching
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 35 percent hydrogen peroxide seven days after bleaching
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 35 percent hydrogen peroxide fourteen days after bleaching
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 35 percent hydrogen peroxide twenty-one days after bleaching
Number of subjects: 20

Group type: COMPARATOR
Intervention: No bleaching treatment (controls)
Number of subjects: 20
Study: 17394960

Group type: EXPERIMENTAL
Intervention: Isosorbide‐5‐mononitrate (IS‐5‐MN) 120 mg once daily for 7 days
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Vitamin C (24 mg/min) during intra-arterial coinfusion after IS‐5‐MN therapy
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 16240937

Group type: EXPERIMENTAL
Intervention: Diazepam (DZ; 10 mg/d) for 14 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 12167793

Group type: EXPERIMENTAL
Intervention: Corline Heparin Surface with standard dose of systemic heparin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Corline Heparin Surface with high dose of systemic heparin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Corline Heparin Surface with low dose of systemic heparin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Uncoated surface with standard dose of systemic heparin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Shed mediastinal blood
Number of subjects: 60
Study: 10460530

Group type: EXPERIMENTAL
Intervention: Lamotrigine 300 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8591104

Group type: EXPERIMENTAL
Intervention: Danazol (400 mg/day orally for 4 to 6 months)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Buserelin (900 micrograms/day intranasally for 4 to 6 months)
Number of subjects: 247
Study: 2699207

Group type: EXPERIMENTAL
Intervention: d-fenfluramine (15 mg p.o. twice daily)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: d-fenfluramine
Number of subjects: 18
Study: 400192

Group type: EXPERIMENTAL
Intervention: Vi‐Siblin
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Lunelax
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 30418322

Group type: EXPERIMENTAL
Intervention: Traumatic Brain Injury (TBI)
Number of subjects: 6929

Group type: COMPARATOR
Intervention: Noninjured individuals (control group)
Number of subjects: 6929
Study: 30241275

Group type: EXPERIMENTAL
Intervention: Olanzapine-containing regimen (acute phase: olanzapine, ondansetron, dexamethasone; delayed phase: olanzapine, ondansetron)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Ondansetron/dexamethasone regimen (acute phase: ondansetron, dexamethasone; delayed phase: ondansetron)
Number of subjects: 131
Study: 27216835

Group type: EXPERIMENTAL
Intervention: 1mg/kg ketamine
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: 1.5mg/kg ketamine
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: 2mg/kg ketamine
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: All doses of ketamine
Number of subjects: 171
Study: 24281396

Group type: EXPERIMENTAL
Intervention: Collaborative Stepped Care (CSC)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 180
Study: 22758599

Group type: EXPERIMENTAL
Intervention: Peer-led asthma self-management program
Number of subjects: 112

Group type: COMPARATOR
Intervention: Adult-led asthma self-management program
Number of subjects: 112
Study: 20642544

Group type: EXPERIMENTAL
Intervention: Eltrombopag 50 mg
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Eltrombopag 150 mg
Number of subjects: 87

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 17554160

Group type: EXPERIMENTAL
Intervention: Stationary cycling (n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nonexercising control group (n = 10)
Number of subjects: 20
Study: 16351339

Group type: EXPERIMENTAL
Intervention: Even Start family literacy program
Number of subjects: 463

Group type: COMPARATOR
Intervention: Control families
Number of subjects: 463
Study: 11212158

Group type: EXPERIMENTAL
Intervention: Celecoxib 100 mg twice daily
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Ketoprofen 100 mg twice daily
Number of subjects: 246

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study: 9041904

Group type: EXPERIMENTAL
Intervention: Home-based weight-bearing exercise program established by a physiotherapist
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 42
Study: 7524016

Group type: EXPERIMENTAL
Intervention: Auditory treatment
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Multimodal treatment
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Kinesthetic treatment
Number of subjects: 61

Group type: COMPARATOR
Intervention: Visual treatment
Number of subjects: 61
Study: 3215041

Group type: EXPERIMENTAL
Intervention: Intravenous alifedrine 20 mg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Intravenous alifedrine 40 mg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Oral alifedrine 40 mg
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 31276430

Group type: EXPERIMENTAL
Intervention: Caregiver-reported preventive medication use
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Preventive medication availability at home
Number of subjects: 335

Group type: COMPARATOR
Intervention: Discontinuous insurance in the prior year
Number of subjects: 335

Group type: COMPARATOR
Intervention: Medication sharing
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Filled a preventive medication in the past year (subset with pharmacy records)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Preventive medication at home (subset with pharmacy records)
Number of subjects: 335

Group type: COMPARATOR
Intervention: Caregiver report of no preventive medication use in the past 2 weeks
Number of subjects: 335

Group type: COMPARATOR
Intervention: Discontinuous insurance
Number of subjects: 335

Group type: COMPARATOR
Intervention: Caregiver education ≥ HS
Number of subjects: 335
Study: 31870325

Group type: EXPERIMENTAL
Intervention: Low-dose high-frequency clinical mentorship in EmONC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control hospital
Number of subjects: 0